BHVN

SEC source: 0001562180-22-007074 · primarydocument.xml · nonDerivative · entry 2

Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 514,445

F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares.

SEC source: 0001562180-22-007074 · primarydocument.xml · nonDerivative · entry 1

Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 461,470

F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").

SEC source: 0001562180-22-007176 · primarydocument.xml · nonDerivative · entry 1

Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 569,309

F1 · shares: Effective as of the pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares pursuant to the Separation and Distribution Agreement, dated as of May 9, 2022, by and among RemainCo, the Issuer and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2)

F2 · shares: (Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares.

F3 · shares: This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 105,950 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares; however, as reflected in this amendment, 52,975 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. There were no other changes made to the information in the Original Form 4.

SEC source: 0001562180-22-007175 · primarydocument.xml · nonDerivative · entry 1

HUGIN ROBERT J · CIK 0001232505 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,959

F1 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.

F2 · shares: This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 3,263 shares were withheld by the Issuer in connection with the share settlement to cover the cost of the stock options; however, as reflected in this amendment, 9,790 shares were withheld by the Issuer in connect with the share settlement to cover the cost of the stock options. There were no other changes made to the information in the Original Form 4.

SEC source: 0001562180-22-007174 · primarydocument.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,178

F1 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.

F2 · shares: This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 5,507 shares were withheld by the Issuer in connection with the share settlement to cover the cost of the stock options; however, as reflected in this amendment, 9,699 shares were withheld by the Issuer in connect with the share settlement to cover the cost of the stock options. There were no other changes made to the information in the Original Form 4.